Tetrabromobisphenol A (TBBPA): Possible modes of action of toxicity and carcinogenicity in rodents

•Modes of action for different toxicities of TBBPA were evaluated.•Uterine tumors likely formed by changes in estrogen disposition due to induction of estrogen sulfation.•Modes-of-action for the small changes in thyroid hormone levels after TBBPA administration are discussed. Due to potential consum...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Food and chemical toxicology 2015-06, Vol.80, p.206-214
Hauptverfasser: Lai, David Y., Kacew, Sam, Dekant, Wolfgang
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Modes of action for different toxicities of TBBPA were evaluated.•Uterine tumors likely formed by changes in estrogen disposition due to induction of estrogen sulfation.•Modes-of-action for the small changes in thyroid hormone levels after TBBPA administration are discussed. Due to potential consumer exposures, the toxicity of tetrabromobisphenol A (TBBPA) has been extensively studied. Reviews of TBBPA concluded no concerns regarding human health risks. The low toxicity of TBBPA is consistent with low bioavailability. However, some oral toxicity studies in rodents with TBBPA reported changes in thyroid hormone levels and a carcinogenicity study with TBBPA showed increased incidences of uterine tumors in rats. This review analyzes several modes of action (MoA) that may account for the observed thyroxine hormone changes and the uterine tumors. It concludes that the potential modes of action for thyroid changes induced by TBBPA are expected to exhibit a threshold for adverse effects due to the ability of the mammalian organism to compensate small changes in thyroid hormone levels. Regarding MoAs for the uterine tumors, TBBPA does not exert genotoxic or estrogenic effects. Available evidence suggests that TBBPA may increase levels of circulating estrogens by a competitive inhibition of estrogen conjugation and produce uterine tumors by promoting pre-existing Tp53-mutations due to increased estrogen levels resulting in increased cell proliferation.
ISSN:0278-6915
1873-6351
DOI:10.1016/j.fct.2015.03.023